Dr. Hongbo Lu, is a Managing Partner with Lilly Asia Ventures (LAV). Prior to joining LAV, Dr. Lu had a tenure of over five years as a Managing Director at OrbiMed Advisors, as well as a senior biotech analyst at Piper Jaffray & Co prior. Dr. Lu has over 20 years of investment and operational experience in healthcare industry. She served and is serving on the board of a number of companies including publicly listed CrownBio (6554.TT, acquired by JSR), Turing Point Therapeutics (TPTX), Avedro (AVDR, acquired by Glaukos), Passage (PASG, observer), as well as private companies. Dr. Lu received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honor from Tsinghua University.